At Exelixis, our vision is to be a world-class commercial biotechnology company.

We believe that we can achieve this with an approach of focused excellence in everything that we do - in working efficiently, in making data-driven decisions quickly, in advancing promising compounds rapidly and in leveraging our robust pipeline to establish partnerships and licensing agreements with leading biotechnology and pharmaceutical companies. The outcome of that strategy to-date is a diverse and quality pipeline of 14 compounds focused on oncology.

Our compounds target multiple receptor tyrosine kinases simultaneously, as well as components of key components of downstream signaling pathways that play important roles in cancer and metabolic diseases. With world-class discovery capabilities, we have an engine to drive continued replenishment of our clinical pipeline, creating a flow of ongoing opportunities for creating value in the clinic and the marketplace.

We take a pragmatic approach to product development, internally developing programs with clear and relatively short paths to market and working with partners to develop those programs with more costly or complex development trajectories. Our current focus is on undertaking a vigorous and expansive clinical development program for our lead compound XL184 with our partner, Bristol-Myers Squibb Company, while making strategic investments in earlier pipeline programs with an eye toward reaching “go/no-go” decisions as efficiently as possible. As these earlier programs progress, we intend to maintain our strategy of balancing internal and collaborative development programs with out-licensing transactions.

Aware that many of today's patients with cancer and other serious diseases have significant unmet medical needs, we are driven by a sense of urgency that mandates that we think large and move fast, pursuing a better way to better medicine.